1. An evaporated fuel treatment device for a motorcycle, comprising:
a fuel tank which is arranged below a rider’s seat and is supported on a vehicle body frame;
a power unit, which includes an engine generating power for driving a rear wheel is arranged below the fuel tank and is swingably supported on the vehicle body frame; and
a charge pipe passage which introduces a fuel gas from the fuel tank to an engine body such that the fuel gas evaporated in the fuel tank is absorbed by oil in the engine body of the engine, wherein
the charge pipe passage includes,
a first engine-side pipe passage part which is arranged above the engine body in a vertically extending manner on one side of the engine body in a vehicle widthwise direction,
a second engine-side pipe passage part which is connected to a lower end of the first engine-side pipe passage part on a first side in the vehicle widthwise direction and extends from the first side to a second side in the vehicle widthwise direction above the engine body, and
a third engine-side pipe passage part which is connected to the second engine-side pipe passage part on the second side in the vehicle widthwise direction and is connected to the engine body, and
a frame-side support part which supports the first engine-side pipe passage part and is mounted on the vehicle body frame,
an engine-side support part, which supports the second engine-side pipe passage part, is mounted on the engine, and at least a part of the charge pipe passage between the engine-side support part and the frame-side support part is formed of an elastic tube.
2. The evaporated fuel treatment device for a motorcycle according to claim 1, wherein the engine body comprises:
a crankcase and
a cylinder head which is arranged in front of the crankcase, and wherein
the second engine-side pipe passage part is arranged so as to pass below an intake device which extends rearwardly from an upper side surface of the cylinder head.
3. The evaporated fuel treatment device for a motorcycle according to claim 2, wherein
the engine-side support part is mounted on the engine at a position closer to the first side in the vehicle widthwise direction than the intake device as viewed in a plan view.
4. The evaporated fuel treatment device for a motorcycle according to claim 1, wherein the vehicle body frame comprises:
a pair of left and right seat frames which have inclined parts extending rearwardly and upwardly respectively, wherein
the power unit is swingably supported on the vehicle body frame below the seat frames, and
the frame-side support part is arranged at an oblique rearward and upward position from the engine-side support part and is mounted on the inclined part of the seat frame on the first side in the vehicle widthwise direction out of both seat frames.
5. The evaporated fuel treatment device for a motorcycle according to claim 4, wherein a cross member is provided between the pair of seat frames behind the frame-side support part,
the fuel tank, which is arranged behind the cross member, is supported on both seat frames, and
the charge pipe passage comprises:
a communication pipe passage part which is connected to an upper end of the first engine-side pipe passage part on the first side of the vehicle in a widthwise direction, and extends toward the second side of the vehicle in a widthwise direction along the cross member, and is connected to the fuel tank.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-49. (canceled)
50. A pharmaceutical composition containing a tablet, granule, or fine granule, or a capsule containing the tablet, the granules, or the fine granules, in which a release of an active ingredient is controlled,
wherein the pharmaceutical composition comprises a first component and a second component, each of which has different release properties of the active ingredient relative to the other component,
each of the first and second components comprises a core particle containing the active ingredient, which is at least one benzimidazole proton pump inhibitor (PPI) or a salt thereof,
a release of the active ingredient in the first component is controlled by a release-controlled coating layer formed on the core particle containing the active ingredient,
the release-controlled coating layer contains a pH-dependently soluble polymer, which comprises one polymeric substance or more than one polymeric substances having different release properties from each other,
a release of the active ingredient in the second component is controlled by an enteric coating layer, and
the first component and the second component individually contain a sufficient amount of the active ingredient to raise a plasma level of the active ingredient in a mammal to whom the pharmaceutical composition is administered to at least 100 ngml.
51. The pharmaceutical composition according to claim 50,
wherein the release controlled coating layer of the first component comprises a pH-dependently soluble polymer soluble in pH range of 6.0 to 7.5, and the enteric coating layer of the second component releases the active ingredient in a pH range of no less than 5.0 to no more than 6.0.
52. The pharmaceutical composition according to claim 50, wherein the pH-dependently soluble release-controlled coating layer comprises one polymeric substance or more than one polymeric substances having different release properties selected from the group consisting of hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, carboxymethylethyl cellulose, methyl methacrylate-methacrylic acid copolymer, methacrylic acid-ethyl acrylate copolymer, methacrylic acid-methyl acrylate-methyl methacrylate copolymer, hydroxypropyl cellulose acetate succinate, polyvinyl acetate phthalate and shellac.
53. The pharmaceutical composition according to claim 50, wherein the composition is a capsule containing the tablet, the granules, or the fine granules.
54. The pharmaceutical composition according to claim 53, wherein the composition is a capsule containing the granules.
55. The pharmaceutical composition according to claim 50, wherein the composition releases the active ingredient from the first component and the second component so that the plasma level of at least 100 ngml in the mammal continues for at least 8 hours.
56. The pharmaceutical composition according to claim 50, wherein the first component and the second component individually contain a sufficient amount of the active ingredient to raise the plasma level in the mammal to at least 300 ngml.
57. A pharmaceutical composition containing a tablet, granule, or fine granule, or a capsule containing the tablet, the granules, or the fine granules, in which a release of an active ingredient is controlled,
wherein the pharmaceutical composition comprises a first component and a second component, each of which has different release properties of the active ingredient relative to the other component,
each of the first and second components comprises a core particle containing the active ingredient,
a release of the active ingredient in the first component is controlled by a release-controlled coating layer formed on the core particle containing the active ingredient,
the release-controlled coating layer contains a pH-dependently soluble polymer, which comprises one polymeric substance or more than one polymeric substances having different release properties from each other,
a release of the active ingredient in the second component is controlled by an enteric coating layer,
the first component and the second component individually contain a sufficient amount of the active ingredient to raise a plasma level of the active ingredient in a mammal to whom the pharmaceutical composition is administered to at least 100 ngml, and
the active ingredient is represented by formula (I\u2032):
wherein ring C\u2032 is an optionally substituted benzene ring or an optionally substituted aromatic monocyclic heterocyclic ring, R0 is a hydrogen atom, an optionally substituted aralkyl group, acyl group or acyloxy group, R1, R2 and R3 are the same or different and are a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group or an optionally substituted amino group, and Y represents a nitrogen atom or CH; or a salt thereof or an optically active isomer thereof.
58. A pharmaceutical composition containing a tablet, granule, or fine granule, or a capsule containing the tablet, the granules, or the fine granules, in which a release of an active ingredient is controlled,
wherein the pharmaceutical composition comprises a first component and a second component, each of which has different release properties of the active ingredient relative to the other component,
each of the first and second components comprises a core particle containing the active ingredient, which is at least one benzimidazole proton pump inhibitor (PPI) or a salt thereof,
a release of the active ingredient in the first component is controlled by a release-controlled coating layer formed on the core particle containing the active ingredient,
the release-controlled coating layer contains a pH-dependently soluble polymer, which comprises one polymeric substance or more than one polymeric substances having different release properties from each other,
a release of the active ingredient in the second component is controlled by an enteric coating layer, and
the active ingredient contained in the first component and the second component is released in a pulsatile manner.
59. The pharmaceutical composition according to claim 58, wherein the release controlled coating layer of the first component comprises a pH-dependently soluble polymer soluble in pH range of 6.0 to 7.5, and the enteric coating layer of the second component releases the active ingredient in a pH range of no less than 5.0 to no more than 6.0.
60. The pharmaceutical composition according to claim 58, wherein the pH-dependently soluble release-controlled coating layer comprises one polymeric substance or more than one polymeric substances having different release properties selected from the group consisting of hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, carboxymethylethyl cellulose, methyl methacrylate-methacrylic acid copolymer, methacrylic acid-ethyl acrylate copolymer, methacrylic acid-methyl acrylate-methyl methacrylate copolymer, hydroxypropyl cellulose acetate succinate, polyvinyl acetate phthalate and shellac.
61. The pharmaceutical composition according to claim 58, wherein the composition is a capsule containing the tablet, the granules, or the fine granules.
62. The pharmaceutical composition according to claim 61, wherein the composition is a capsule containing the granules.
63. The pharmaceutical composition according to claim 58, wherein the first component and the second component individually contain a sufficient amount of the active ingredient to raise a plasma level of the active ingredient in a mammal to whom the pharmaceutical composition is administered to at least 100 ngml.
64. The pharmaceutical composition according to claim 63, wherein the composition releases the active ingredient from the first component and the second component so that the plasma level of at least 100 ngml in the mammal continues for at least 8 hours.
65. The pharmaceutical composition according to claim 58, wherein the first component and the second component individually contain a sufficient amount of the active ingredient to raise a plasma level of the active ingredient in a mammal to whom the pharmaceutical composition is administered to at least 300 ngml.
66. A pharmaceutical composition containing a tablet, granule, or fine granule, or a capsule containing the tablet, the granules, or the fine granules, in which a release of an active ingredient is controlled,
wherein the pharmaceutical composition comprises a first component and a second component, each of which has different release properties of the active ingredient relative to the other component,
each of the first and second components comprises a core particle containing the active ingredient,
a release of the active ingredient in the first component is controlled by a release-controlled coating layer formed on the core particle containing the active ingredient,
the release-controlled coating layer contains a pH-dependently soluble polymer, which comprises one polymeric substance or more than one polymeric substances having different release properties from each other,
a release of the active ingredient in the second component is controlled by an enteric coating layer,
the active ingredient contained in the first component and the second component is released in a pulsatile manner, and
the active ingredient is represented by formula (I\u2032):
wherein ring C\u2032 is an optionally substituted benzene ring or an optionally substituted aromatic monocyclic heterocyclic ring, R0 is a hydrogen atom, an optionally substituted aralkyl group, acyl group or acyloxy group, R1, R2 and R3 are the same or different and are a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group or an optionally substituted amino group, and Y represents a nitrogen atom or CH; or a salt thereof or an optically active isomer thereof.
67. A pharmaceutical composition containing a tablet, granule, or fine granule, or a capsule containing the tablet, the granules, or the fine granules, in which a release of an active ingredient is controlled,
wherein the pharmaceutical composition comprises a first component and a second component, each of which has different release properties of the active ingredient relative to the other component,
each of the first and second components comprises a core particle containing the active ingredient, which is at least one benzimidazole proton pump inhibitor (PPI) or a salt thereof,
a release of the active ingredient in the first component is controlled by a release-controlled coating layer formed on the core particle containing the active ingredient,
the release-controlled coating layer contains a pH-dependently soluble polymer, which comprises one polymeric substance or more than one polymeric substances having different release properties from each other,
a release of the active ingredient in the second component is controlled by an enteric coating layer, and
an amount of the active ingredient in the first component is at least 50% more than an amount of the active ingredient in the second component.
68. The pharmaceutical composition according to claim 67, wherein an amount of the active ingredient in the first component is at least twice of an amount of the active ingredient in the second component.
69. The pharmaceutical composition according to claim 67, wherein an amount of the active ingredient in the first component is at least three times an amount of the active ingredient in the second component.
70. The pharmaceutical composition according to claim 67, wherein the release controlled coating layer of the first component comprises a pH-dependently soluble polymer soluble in pH range of 6.0 to 7.5, and the enteric coating layer of the second component releases the active ingredient in a pH range of no less than 5.0 to no more than 6.0.
71. The pharmaceutical composition according to claim 67, wherein the pH-dependently soluble release-controlled coating layer comprises one polymeric substance or more than one polymeric substances having different release properties selected from the group consisting of hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, carboxymethylethyl cellulose, methyl methacrylate-methacrylic acid copolymer, methacrylic acid-ethyl acrylate copolymer, methacrylic acid-methyl acrylate-methyl methacrylate copolymer, hydroxypropyl cellulose acetate succinate, polyvinyl acetate phthalate and shellac.
72. The pharmaceutical composition according to claim 67, wherein the composition is a capsule containing the tablet, the granules, or the fine granules.
73. The pharmaceutical composition according to claim 72, wherein the composition is a capsule containing the granules.
74. The pharmaceutical composition according to claim 67, wherein the first component and the second component individually contain a sufficient amount of the active ingredient to raise a plasma level of the active ingredient in a mammal to whom the pharmaceutical composition is administered to at least 100 ngml.
75. The pharmaceutical composition according to claim 74, wherein the composition releases the active ingredient from the first component and the second component so that the plasma level of at least 100 ngml in the mammal continues for at least 8 hours.
76. The pharmaceutical composition according to claim 67, wherein the first component and the second component individually contain a sufficient amount of the active ingredient to raise a plasma level of the active ingredient in a mammal to whom the pharmaceutical composition is administered to at least 300 ngml.
77. A pharmaceutical composition containing a tablet, granule, or fine granule, or a capsule containing the tablet, the granules, or the fine granules, in which a release of an active ingredient is controlled,
wherein the pharmaceutical composition comprises a first component and a second component, each of which has different release properties of the active ingredient relative to the other component,
each of the first and second components comprises a core particle containing the active ingredient,
a release of the active ingredient in the first component is controlled by a release-controlled coating layer formed on the core particle containing the active ingredient,
the release-controlled coating layer contains a pH-dependently soluble polymer, which comprises one polymeric substance or more than one polymeric substances having different release properties from each other,
a release of the active ingredient in the second component is controlled by an enteric coating layer,
an amount of the active ingredient in the first component is at least 50% more than an amount of the active ingredient in the second component, and
the active ingredient is represented by formula (I\u2032):
wherein ring C\u2032 is an optionally substituted benzene ring or an optionally substituted aromatic monocyclic heterocyclic ring, R0 is a hydrogen atom, an optionally substituted aralkyl group, acyl group or acyloxy group, R1, R2 and R3 are the same or different and are a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group or an optionally substituted amino group, and Y represents a nitrogen atom or CH; or a salt thereof or an optically active isomer thereof.
78. A pharmaceutical composition containing a tablet, granule, or fine granule, or a capsule containing the tablet, the granules, or the fine granules, in which a release of an active ingredient is controlled,
wherein the pharmaceutical composition comprises a first component and a second component, each of which has different release properties of the active ingredient relative to the other component,
each of the first and second components comprises a core particle containing the active ingredient, which is at least one benzimidazole proton pump inhibitor (PPI) or a salt thereof,
a release of the active ingredient in the first component is controlled by a release-controlled coating layer formed on the core particle containing the active ingredient,
the release-controlled coating layer contains a pH-dependently soluble polymer, which comprises one polymeric substance or more than one polymeric substances having different release properties from each other,
a release of the active ingredient in the second component is controlled by an enteric coating layer, and
a total amount of the active ingredient in the first component and the second component is between 5 mg and 150 mg.
79. The pharmaceutical composition according to claim 78, wherein the total amount of the active ingredient in the first component and the second component is between 30 mg and 90 mg.
80. The pharmaceutical composition according to claim 78, wherein the release controlled coating layer of the first component comprises a pH-dependently soluble polymer soluble in pH range of 6.0 to 7.5, and the enteric coating layer of the second component releases the active ingredient in a pH range of no less than 5.0 to no more than 6.0.
81. The pharmaceutical composition according to claim 78, wherein the pH-dependently soluble release-controlled coating layer comprises one polymeric substance or more than one polymeric substances having different release properties selected from the group consisting of hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, carboxymethylethyl cellulose, methyl methacrylate-methacrylic acid copolymer, methacrylic acid-ethyl acrylate copolymer, methacrylic acid-methyl acrylate-methyl methacrylate copolymer, hydroxypropyl cellulose acetate succinate, polyvinyl acetate phthalate and shellac.
82. The pharmaceutical composition according to claim 78, wherein the composition is a capsule containing the tablet, the granules, or the fine granules.
83. The pharmaceutical composition according to claim 82, wherein the composition is a capsule containing the granules.
84. The pharmaceutical composition according to claim 78, wherein the first component and the second component individually contain a sufficient amount of the active ingredient to raise a plasma level of the active ingredient in a mammal to whom the pharmaceutical composition is administered to at least 100 ngml.
85. The pharmaceutical composition according to claim 84, wherein the composition releases the active ingredient from the first component and the second component so that the plasma level of at least 100 ngml in the mammal continues for at least 8 hours.
86. The pharmaceutical composition according to claim 78, wherein the first component and the second component individually contain a sufficient amount of the active ingredient to raise a plasma level of the active ingredient in a mammal to whom the pharmaceutical composition is administered to at least 300 ngml.
87. A pharmaceutical composition containing a tablet, granule, or fine granule, or a capsule containing the tablet, the granules, or the fine granules, in which a release of an active ingredient is controlled,
wherein the pharmaceutical composition comprises a first component and a second component, each of which has different release properties of the active ingredient relative to the other component,
each of the first and second components comprises a core particle containing the active ingredient,
a release of the active ingredient in the first component is controlled by a release-controlled coating layer formed on the core particle containing the active ingredient,
the release-controlled coating layer contains a pH-dependently soluble polymer, which comprises one polymeric substance or more than one polymeric substances having different release properties from each other,
a release of the active ingredient in the second component is controlled by an enteric coating layer,
a total amount of the active ingredient in the first component and the second component is between 5 mg and 150 mg, and
the active ingredient is represented by formula (I\u2032):
wherein ring C\u2032 is an optionally substituted benzene ring or an optionally substituted aromatic monocyclic heterocyclic ring, R0 is a hydrogen atom, an optionally substituted aralkyl group, acyl group or acyloxy group, R1, R2 and R3 are the same or different and are a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group or an optionally substituted amino group, and Y represents a nitrogen atom or CH; or a salt thereof or an optically active isomer thereof.
88. A method to prevent or treat a gastrointestinal disorder in a mammal in need thereof comprising administering to the mammal a pharmaceutical composition containing a tablet, granule, or fine granule, or a capsule containing the tablet, the granules, or the fine granules, in which a release of an active ingredient is controlled,
wherein the pharmaceutical composition comprises a first component and a second component, each of which has different release properties of the active ingredient relative to the other component,
each of the first and second components comprises a core particle containing the active ingredient, which is at least one benzimidazole proton pump inhibitor (PPI) or a salt thereof,
a release of the active ingredient in the first component is controlled by a release-controlled coating layer formed on the core particle containing the active ingredient,
the release-controlled coating layer contains a pH-dependently soluble polymer, which comprises one polymeric substance or more than one polymeric substances having different release properties from each other,
a release of the active ingredient in the second component is controlled by an enteric coating layer, and
the gastrointestinal disorder is caused by at least one selected from the group consisting of ulcer, gastric juice secretion, mucosa damage, and Helicobacter pylori.
89. The method to prevent or treat a gastrointestinal disorder according to claim 88,
wherein the gastrointestinal disorder is at least one selected from the group consisting of digestive ulcer, Zollinger-Ellison syndrome, gastritis, reflux esophagitis, symptomatic gastroesophageal reflux disease (symptomatic GERD) with no esophagitis, non-ulcer dyspepsia (NUD), gastric cancer, and gastric MALT lymphoma.
90. The method to prevent or treat a gastrointestinal disorder according to claim 88,
wherein the mammal is human.
91. The method to prevent or treat a gastrointestinal disorder according to claim 88,
wherein the release controlled coating layer of the first component of the pharmaceutical composition comprises a pH-dependently soluble polymer soluble in pH range of 6.0 to 7.5, and the enteric coating layer of the second component releases the active ingredient in a pH range of no less than 5.0 to no more than 6.0.
92. The method to prevent or treat a gastrointestinal disorder according to claim 88,
wherein the pH-dependently soluble release-controlled coating layer comprises one polymeric substance or more than one polymeric substances having different release properties selected from the group consisting of hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, carboxymethylethyl cellulose, methyl methacrylate-methacrylic acid copolymer, methacrylic acid-ethyl acrylate copolymer, methacrylic acid-methyl acrylate-methyl methacrylate copolymer, hydroxypropyl cellulose acetate succinate, polyvinyl acetate phthalate and shellac.
93. The method to prevent or treat a gastrointestinal disorder according to claim 88,
wherein the composition is a capsule containing the tablet, the granules, or the fine granules.
94. The method to prevent or treat a gastrointestinal disorder according to claim 93,
wherein the composition is a capsule containing the granules.
95. The method to prevent or treat a gastrointestinal disorder according to claim 88, wherein the first component and the second component of the pharmaceutical composition individually contain a sufficient amount of the active ingredient to raise a plasma level of the active ingredient in a mammal to whom the pharmaceutical composition is administered to at least 100 ngml.
96. The method to prevent or treat a gastrointestinal disorder according to claim 95, wherein the composition releases the active ingredient from the first component and the second component of the pharmaceutical composition so that the plasma level of at least 100 ngml in the mammal continues for at least 8 hours.
97. The method to prevent or treat a gastrointestinal disorder according to claim 88, wherein the first component and the second component individually contain a sufficient amount of the active ingredient to raise a plasma level of the active ingredient in a mammal to whom the pharmaceutical composition is administered to at least 300 ngml.
98. A method to prevent or treat a gastrointestinal disorder in a mammal in need thereof comprising administering to the mammal a pharmaceutical composition containing a tablet, granule, or fine granule, or a capsule containing the tablet, the granules, or the fine granules, in which a release of an active ingredient is controlled,
wherein the pharmaceutical composition comprises a first component and a second component, each of which has different release properties of the active ingredient relative to the other component,
each of the first and second components comprises a core particle containing the active ingredient,
a release of the active ingredient in the first component is controlled by a release-controlled coating layer formed on the core particle containing the active ingredient,
the release-controlled coating layer contains a pH-dependently soluble polymer, which comprises one polymeric substance or more than one polymeric substances having different release properties from each other,
a release of the active ingredient in the second component is controlled by an enteric coating layer,
the gastrointestinal disorder is caused by at least one selected from the group consisting of ulcer, gastric juice secretion, mucosa damage, and Helicobacter pylori, and
the active ingredient is represented by formula (I\u2032):
wherein ring C\u2032 is an optionally substituted benzene ring or an optionally substituted aromatic monocyclic heterocyclic ring, R0 is a hydrogen atom, an optionally substituted aralkyl group, acyl group or acyloxy group, R1, R2 and R3 are the same or different and are a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group or an optionally substituted amino group, and Y represents a nitrogen atom or CH; or a salt thereof or an optically active isomer thereof.
99. A pharmaceutical composition containing a tablet, granules, or a capsule containing the tablet, the granules, or the fine granules, in which a release of an active ingredient is controlled,
wherein the pharmaceutical composition comprises a first component and a second component, each of which has different release properties of the active ingredient relative to the other component,
each of the first component and the second component comprises a core particle containing the active ingredient, which is at least one benzimidazole proton pump inhibitor (PPI) or a salt thereof,
a release of the active ingredient in the first component is controlled for delivery in a pH range of 6.0 to 7.5,
a release of the active ingredient in the second component is controlled for delivery in a range of no less than 5.0 to no more than 6.0, and
the first component and the second component individually contain a sufficient amount of the active ingredient to raise a plasma level of the active ingredient in a mammal to whom the pharmaceutical composition is administered to at least 100 ngml.
100. The pharmaceutical composition according to claim 99, wherein the composition releases the active ingredient from the first component and the second component so that the plasma level of at least 100 ngml in the mammal continues for at least 8 hours.
101. The pharmaceutical composition according to claim 99, wherein the first component and the second component individually contain a sufficient amount of the active ingredient to raise the plasma level in the mammal to at least 300 ngml.
102. A pharmaceutical composition containing a tablet, granule, or fine granule, or a capsule containing the tablet, the granules, or the fine granules, in which a release of an active ingredient is controlled,
wherein the pharmaceutical composition comprises a first component and a second component, each of which has different release properties of the active ingredient relative to the other component,
each of the first and second components comprises a core particle containing the active ingredient,
a release of the active ingredient in the first component is controlled for delivery in a pH range of 6.0 to 7.5,
a release of the active ingredient in the second component is controlled for delivery in a range of no less than 5.0 to no more than 6.0, and
the first component and the second component individually contain a sufficient amount of the active ingredient to raise a plasma level of the active ingredient in a mammal to whom the pharmaceutical composition is administered to at least 100 ngml, and
the active ingredient is represented by formula (I\u2032):
wherein ring C\u2032 is an optionally substituted benzene ring or an optionally substituted aromatic monocyclic heterocyclic ring, R0 is a hydrogen atom, an optionally substituted aralkyl group, acyl group or acyloxy group, R1, R2 and R3 are the same or different and are a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group or an optionally substituted amino group, and Y represents a nitrogen atom or CH; or a salt thereof or an optically active isomer thereof.